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Abstract
Recombinant antibody phage display technology has been used to mimic many aspects of the processes that govern the
generation and selection of high-affinity natural human antibodies in the human immune system, especially for infectious
disease prophylaxis. An anti-rabies virus immunized phage-display Fab library was constructed from peripheral blood
lymphocytes from vaccinated volunteers. The immunized antibody library, with a diversity of 6.7610
8, was used to select
and produce antibodies that bound to rabies virus glycoprotein. After five rounds of immobilized fixed rabies virion
panning, four unique DNA sequences were found in the higher binding clones, and only one, Fab094, showed
neutralization activity. Fab094 components were analyzed by ELISA, immunoprecipitation and immunofluorescent staining.
ELISA and immunofluorescence showed that Fab094 bound specifically to rabies virions. Immunoprecipitation and mass
spectrometry showed that Fab094 reacted with rabies virus glycoprotein. To improve the penetration power of Fab094
antibodies, we developed Fab094 calcium phosphate nanoparticles (Fab094-CPNPs) and tested their efficacy. The rapid
fluorescent focus inhibition test indicated that the neutralizing antibody titers of Fab094 and Fab094-CPNPs were reached
at 200.17 IU/Kg and 246.12 IU/Kg, respectively. These findings were confirmed in vivo in a Kunming mouse challenge
model. Our results demonstrate that human Fab094 and Fab094-CPNPs are efficacious candidate drugs to replace rabies
immunoglobulin in post-exposure prophylaxis (PEP).
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Introduction
Rabies is a zoonotic viral disease that infects wild as well as
domestic animals [1]. It is estimated that at least 500,000 people
receive post-exposure vaccination and that 55,000 people die from
rabies each year [2], especially in Africa and Asia where rabies is
endemic, and where successful canine rabies vaccination or
control programs have not been implemented [3]. According to
the categorization of exposure defined by the World Health
Organization (WHO), the most severe cases (category III) require
wound cleaning, rabies vaccination, and direct wound infiltration
with rabies immunoglobulin (RIG). Both purified equine rabies
immunoglobulin (ERIG) and human immunoglobulin (HRIG) are
used in rabies endemic areas [3,4]. ERIG that is manufactured
presently is highly purified and the occurrence of adverse events
has been reduced significantly, but serious reactions, including
anaphylaxis and serum sickness caused by heteroantigens, can
occur in spite of a negative skin test [5]. HRIG is purified from
carefully selected donors, and processing eliminates viral contam-
inants, but it still can increase susceptibility to various infections,
including HIV and hepatitis viruses.
Alternatives to HRIG and ERIG should be considered,
including human monoclonal antibodies, human recombinant
antibodies [6], and antibodies from other animals, such as sheep
[7]. Ray et al. have described two rabies-virus-neutralizing scFv–
Fc fusion proteins isolated from a human synthetic scFv phage
display library [8]. Ando et al. have reported two Fab
preparations, EP5G3 and GD2D12, that were isolated from a
phage display library, which have neutralizing activity against
rabies virus strain CVS when assayed by rapid fluorescent focus
inhibition test (RFFIT) [1]. Houimel et al. also have reported three
Fabs isolated from a recombinant immune antibody library [2].
However, the neutralizing activity of these Fab antibodies has not
been confirmed in vivo.
In recent years, new strategies for cancer treatment based on
drug-loaded nanoparticulate formulations have emerged [9].
Nanoparticles are promising drug carriers that show high drug-
loading efficiency, minor drug leakage, and good storage stability,
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Above all, nanoparticles have an enhanced permeability and
retention (EPR) effect [11]. Moreover, their body biodistribution
and permeability in tissues can be controlled by size and surface
properties [12].
The current study describes the isolation of human Fabs with
rabies-virus-neutralizing activity from a human immunized phage
display library using peripheral blood lymphocytes. In addition,
we developed Fab094-calcium phosphate nanoparticles (CPNPs)
and tested their efficacy in vitro neutralization assay and animal
model in vivo.
Materials and Methods
Rabies strains and cells
Rabies virus strain CTN (which has 83.2–96.8% nucleic acid
and 90.0–97.4% amino acid sequence homology to street strains
[13]), was provided by Wuhan Institute of Virology, Chinese
Academy of Sciences. Rabies virus strain CVS-11 and BHK-21
cells were from the Veterinary Institute of the Academy of Military
Medical Sciences, China. BHK-21 cells were cultured in DMEM
(Gibco, USA) supplemented with 10% fetal bovine serum (FBS,
Gibco, USA). Cell lines were maintained at 37uC under 5% CO2.
Animals
Kunming mice (10–12 g) were obtained from the Experimental
Animal Center of the Academy of Military Medical Sciences of
China. All animal breeding and experiments were approved by the
Veterinary Institute of the Academy of Military Medical Sciences
animal Ethics Committee [Project Numbers SYXK (ARMY)
2009- 045].
Preparation of cDNA for library construction
Lymphocytes were collected from 45 healthy donors who were
immunized with rabies vaccine (Flury LEP; Chiron Behring
Vaccines Pvt. Ltd). The volunteers got their signed, informed
consent to participate, and the Ethics Committee of Nanjing
Medical University approved the study.
Up to 10 ml anticoagulant blood was diluted with 10 ml PBS.
Human peripheral blood mononuclear cells were isolated on a
Ficoll-Pacque gradient and total RNA was prepared by using an
RNA Purification kit (QIAGEN, Valencia, CA, USA). First-strand
cDNA was synthesized from total RNA by using a First-strand
cDNA Synthesis kit (Invitrogen, USA) with Oligo-dT18.
Construction of Fab library
For the amplification of Fab gene segments, a unique three-step
PCR was used [14]. The V regions of heavy and light chains, CH1
(with IgG1 isotype) and CL (including k and l) were amplified first.
In a second step, the amplified VH,V L,C H1 and CL were joined
together in an overlap PCR to amplify the Fd and light chains.
The Fd and L chains were mixed in equal ratios to generate full-
length Fab fragments. The light- and heavy-chain Fds were spliced
by PCR overlap extension with primers appended with SfiI
restriction sites, as described above. The resultant Fab was
digested with SfiI (Roche Molecular Biochemicals, Mannheim,
Germany), purified on agarose gel, and ligated into the phagemid
pComb3XSS (provided by the Barbas III Laboratory) that had
been cut with the same restriction enzyme.
After ligation, DNA (2 mg) was ethanol-precipitated, resus-
pended in 15 ml of water, and electro-transformed into 300 ml
Escherichia coli XL1-Blue (Stratagene, La Jolla, CA, USA). After
transformation, 5 ml SOC medium was added at room temper-
ature, and the cultures were shaken at 300 rpm for 1 h at 37uC.
After addition of 10 ml pre-warmed (37uC) SB medium that
contained 20 mg/ml ampicillin and 10 mg/ml tetracycline, the
cultures were shaken at 300 rpm for an additional l h. These
cultures were added to 180 ml pre-warmed SB medium that
contained 50 mg/ml ampicillin and 10 mg/ml tetracycline, after
which, 2 ml helper phage VCSM13 (10
12–10
13 PFU/ml) (Strata-
gene) was added, and the cultures were shaken for an additional
1.5 h. Kanamycin (70 mg/ml) was added, and the cultures were
shaken at 37uC overnight.
The cultures were spun down and phages were precipitated by
addition of 4% (w/v) polyethylene glycol 8000 and 3% (w/v)
NaCl, followed by incubation on ice for 30 min, and centrifuga-
tion at 37uC. Phage pellets were resuspended in 2 ml TBS with
1% BSA and microcentrifuged at room temperature for 5 min to
pellet debris. The supernatant was sterilized by passing it through
a 0.22-mm filter and stored at 220uC. This phage display antibody
library was used for the following antigen panning.
Selection of binding phage on immobilized rabies virus
The library was subjected to five rounds of panning, as
previously described [14]. Before being selected with rabies virus,
the phages were incubated with 1610
6 human cells for non-
specific binding, and then panning with rabies virus protein. The
phage library was incubated with 3% BSA for 30 min at room
temperature and transferred onto microplates (Corning, NY,
USA) coated with immobilized inactivated whole viruses of rabies
virus CTN strain, at 0.5 mg/well, for 1 h at 37uC. Unbound
phages were washed off with PBS/0.2% Tween-20 for 10–20
times. Antigen-bound phages were eluted using 0.5 ml trypsin/
EDTA. The eluted phages were used to infect 2 ml fresh
(OD600=0.8) E. coli XL1-Blue cells for 15 min at room
temperature, and 10 ml prewarmed SB medium that contained
20 mg/ml ampicillin and 10 mg/ml tetracycline was added. The
cultures were then shaken for 1 h at 37uC. Further growth, phage
preparation, and panning were repeated as outlined above. After
five rounds of immobilized antigen selection, random monoclonal
phages were selected and screened by phage ELISA.
Monoclonal phage ELISA
Specificity of individual phage Fab and soluble Fab were
assessed by ELISA [15]. EIA/RIA Stripwell (Corning, NY, USA)
96-well plates were coated overnight at 4uC with fixed rabies virus
protein of CTN strain (5 mg/ml), blocked with 1% BSA blocking
buffer, and incubated. The eluted phages from the fifth round of
panning were used to infect E. coli XL1-Blue cells and spread on
LB plates with 50 mg/ml ampicillin and incubated at 37uC
overnight. Single clones were selected randomly to produce phage
as described previously. Fifty microliters of single phage prepara-
tion was added and incubated at room temperature for 1 h. As the
negative control, empty phage was used. After washing twice with
wash buffer (PBS with 0.05% Tween-20), for phage ELISA, 50 ml
horseradish peroxidase (HRP)-conjugated anti-M13 monoclonal
antibody (Amersham, Piscataway, NJ, USA) in milk blocking
buffer (1:2,000 dilution) was added for 1 h at room temperature.
The reaction was visualized with TMB and H2O2 substrate, and
stopped by 2 M H2SO4. Plates were read for OD450 with a
reference wavelength of 630 nm, on a multiscan spectrum
(Thermo Labsystems, USA).
DNA sequence and analysis
High-titer clones were selected and cultured overnight, and the
plasmids were extracted and sequenced. The DNA sequence of
each Fab clone was analyzed with DNAclub and V-BASE2
software online.
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The gene for pComb3XSS-Fab, which was confirmed as the
correct sequence by DNA sequencing, was transformed into E. coli
Top10F’ (Invitrogen, Carlsbad, CA, USA) for expression [16].
Cultures of recombinant bacteria were induced with 1 mM IPTG
(Biosharp) and cultured with shaking at 25uC for 12 h. The
cultures were harvested by centrifugation at 4uC and the cell pellet
was suspended in 200 ml PBS. After sonication, the supernatant
was collected by centrifugation for 30 min (12,000 rpm) at 4uC,
and analyzed for soluble expression of Fab.
The Fab fragment was purified from the supernatant and
medium by affinity chromatography with an ImmunoPure
Immobilized Protein L column (Pierce) using an FPLC system
(Amersham Pharmacia Biotech, Uppsala, Sweden). Fab was eluted
with glycine buffer (pH 2.8). The eluted fractions were concen-
trated by centrifugal filters (10,000 MWCO; Millipore, Bedford,
MA, USA). The prepared Fab fragment which has neutralization
activity (see below) was named as Fab094.
Western blotting analysis
Protein samples were analyzed by electrophoresis on 10% SDS-
PAGE under reducing conditions, and transferred onto nitrocel-
lulose membranes. The membranes were first blocked by
incubation with 5% nonfat milk and then with HRP-conjugated
anti-human IgG (Fab-specific), and finally developed using the
ECL detection system and exposed to X-ray film.
Mass spectrometry (MS)
Rabies virus strain CTN proteins were mixed with 20 mg purified
Fab094 and 50 ml protein-L Sepharose beads (Invitrogen), and
incubated at 4uC overnight with gentle shaking. The immune
complexes were detected by 12% SDS-PAGE under reducing
conditions and transferred onto nitrocellulose membranes. The
commercial mouse anti-rabies virus glycoprotein antibody
C86307M, which reacts with a glycoprotein of rabies, more than 20
different strains from 4 serogroups, including CVS, Lagosbat, Mokola,
Duwenhage were positive in neutralization (Meridian Life Science,
USA), was added to the membranes for1 h at room temperature. The
HRP-conjugated goat anti-mouse IgG was added for another 1 h.
Following further washes, bound antibodies were detected by the
addition of the mixture of H2O2 and DAB, and after incubation for
15 min at 37uC, the reaction was stopped by washing with water.
The bands that corresponded to CTN virus protein on the
polyacrylamide gel were analyzed by MS. Each gel slice was
dissolved in 0.1% trifluoroacetic acid (TFA), desalted, and
concentrated using ZipTips from Millipore. Peptide solution
(0.5 ml) was mixed with 0.5 ml matrix (5 mg/ml a-cyano-4-
hydroxycinnamic acid in 30% acetonitrile/0.1% TFA), spotted
on a target disk, and allowed to air dry. Samples were analyzed by
MS (Bruker Daltonics, Leipzig, Germany). Protein database
searching was performed with the MASCOT search engine
(http://www.matrix science.com; Matrix Science, UK).
Immunofluorescence assay (IFA)
Binding of Fab094 with rabies-virus-infected cells was deter-
mined by IFA. Sub-confluent BHK-21 cells, which were grown in
six-well chambers, were infected with rabies virus strain CVS-11 at
a multiplicity of infection of 0.1. After incubation for 24 h, the
chambers were washed twice with PBS/Tween 20. Diluted Fab094
was added to virus-infected BHK-21 cells. After incubation at room
temperature for 2 h, followed by three washes in 0.5% PBS/Tween
20, FITC-labeled anti-human IgG (Fab-specific) was added at
dilution of 1:100, and the cells were observed under fluorescence
microscopy. The uninfected cells were used as a negative control.
The experiments that involved the use of rabies strain CVS-11 were
performed in a BSL-3 laboratory.
Preparation of Fab094-CPNPs
Fab094-CPNPs were prepared using the adsorption technique [4].
Nanoparticles were prepared by a simple interfacial deposition method
(nanoprecipitation). Briefly, 160 mg CaCl2, 160 mg NaH2PO4 and
160 mg sodium citrate were added to 180 ml distilled water under
magnetic stirring at room temperature for 48 h, sonicated for 1 h,
centrifuged (10,000 rpm, 15 min, 4uC), and the precipitate was
separated. After centrifugation, the precipitate was resuspended in
PBS, and sonicated for 1 h. Then, 10 mg Fab094 was added and
stirred with the above suspensions to absorb the Fab094 at 4uCf o r
24 h. The resultant suspension was centrifuged and the precipitate was
resuspended in pure water. The protein concentration of the
supernatant was determined. Sizes of nanoparticles and Fab094-
CPNPs were measured by Zetasizer-Nano instrument (Malvern, UK).
Neutralization activity detection of Fab094 and Fab094-
CPNPs in vitro
The sample was diluted three fold with DMEM that contained
10% FBS, and placed in a well. The samples were set up in
duplicate. CVS-11 (100 TCID50) was added to each well and
incubated in a 5% CO2 incubator at 37uC for 90 min. BSR cells
were added to each well and incubated for 24 h. Finally, cells were
fixed with 80% acetone and stained with FITC-conjugated anti-
rabies N monoclonal antibody at 37uC for 30 min, and observed
under a fluorescence microscope. Standard anti-rabies serum
(30 IU/ml) was used as positive control. The average of duplicate
samples was determined. The neutralizing antibody titer was
calculated by the Reed–Muench method [17,18].
In vivo Kunming mouse challenge model
A lethal animal model that mimicked rabies exposure was used as
described previously [19–22]. Kunming mice (17 groups of eight
mice, 10–12 g) were infected with 100LD50/0.05 ml rabies virus
CVS-11. Three hours later, prophylaxis was initiated with vaccine
(diluted with PBS; Chiron Behring Vaccines) alone, single antibody
(Fab094 or Fab094-CPNPs) alone, vaccine plus HRIG (20 IU/kg;
Taibang Ltd., China), or vaccine plus 40, 32, 20, 8, 2 or 0.5 IU/kg
single monoclonal antibody (Fab094 or Fab094-CPNPs). As a
negative control, one group was treated with PBS. On day 7, mice
were vaccinated with rabies vaccine again, except for the negative
control group. The mice were examined daily for clinical signs of
rabies and death. The mice were maintained and evaluated at up to
28 days after infection. The experiments that involved the use of
rabies strain CVS-11 were performed in a BSL-3 laboratory. At
necropsy, brain impressions were made and tested for rabies virus
antigen by the direct fluorescent antibody test [16,20].
Data analysis
All data were processed and analyzed by SPSS10.0 Data Editor
(SPSS Inc., Chicago, IL, USA). Fisher’s exact test was used. The
results in comparisons between groups were considered different if
P was ,0.05.
Results
Fab library construction and immobilized antigen
panning
The Fab genes were successful amplified after three-step PCR (data
not shown). The pooled Fab DNA was digested efficiently with SfiIa n d
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create a phage display antibody library with a capacity of 6.7610
8.
After five rounds of panning, 60 individual phage clones were
selected randomly and amplified to test for specific binding to
rabies virus, by phage ELISA (Figure 1). As shown in Fig. 1, 22
clones were representative clones of the 60, which had higher
OD450 value, and analyzed by DNA sequencing and BLAST
analysis, which indicated that four unique phages (named Fab092,
Fab093, Fab094, Fab095) encoded the different Fab DNA
sequences. Unlucky, only Fab094 has the neutralization activity
and Fab 094 DNA sequence has been deposited in GenBank (the
accession numbers: VH was HQ706884 and VL was HQ706885).
Fab expression and purification
The soluble Fab094 was purified from the periplasm of the
bacteria using protein L affinity purification. One liter of the
bacterial cultures typically yielded approximately 2 mg of the finial
purified Fab094 product. The purified Fab094 was verified by
SDS-PAGE and western blotting, which showed two bands at
about 30 and 26 kD (Figure 2).
Co-immunoprecipitation and MS
Immunoprecipitation was carried out with rabies virus strain
CTN protein. Sixty-seven-kilodalton proteins were captured by
Fab094, but they were not found in freeze–thaw lysates of BHK-
21 cells, which are used routinely for rabies virus culture
(Figure 3A). Eight peptide sequences (Table 1) matched with
rabies glycoprotein by MS analysis (Figure 3B) were found when
the identified peptides were compared with the known sequences
of rabies glycoprotein in the SWISS PROT database.
IFA
To ascertain whether Fab094 recognized rabies virus protein,
virus-infected cells were incubated with Fab094 followed by FITC-
labeled anti-human IgG (Fab-specific). The fluorescent antigens
were detected on the surface of virus-infected cells (Figure 4).
These findings suggested that Fab094 recognized the authentic
rabies virus protein.
Construction of Fab094-CPNPs
Four Fab antibody preparations were examined for neutraliza-
tion activity against rabies virus strain CVS-11, but only Fab094
exhibited neutralizing activity (described below). Following,
Fab094 was loaded calcium phosphate nanoparticles and named
as Fab094-CPNPs. The average size of nanoparticle was 260 nm.
Neutralization activity of Fab094 and Fab094-CPNPs in
vitro
The Fab094 neutralizing activity measured by RFFIT was
200.11 IU/mg, while that of Fab094-CPNPs was 246.12 IU/mg.
Fab092, Fab093 and Fab095 failed to show any neutralizing
activity against the CVS-11 strain.
Virus neutralizing activity in vivo
The survival rate against CVS-11 infection is shown in Figure 5.
Data indicated that 40 IU/kg Fab094 or 8 IU/kg Fab094-CPNPs
Figure 1. Fixed rabies virus protein specifically recognized colony- screening-positive phage clones in ELISA. Sixty individual bacterial
clones were selected randomly after the fifth round of selection, to produce recombinant phages. As the negative control, empty phage was used.
These phages were tested for their ability to bind to rabies virus protein by ELISA. Lane 1–22 were the representative clones of the 60, which had
higher OD450 value. Lane NC 1–2 were empty phages.
doi:10.1371/journal.pone.0019848.g001
Figure 2. SDS-PAGE and western blotting analysis of the
protein of purified Fab094. (A) Proteins were separated by 12%
SDS-PAGE and stained with Coomassie Brilliant Blue. Lane 1 shows the
protein of purified Fab094. Lane M contained the molecular-mass
markers. (B) Western blotting analysis of Fab094 with HRP-conjugated
anti-human IgG (Fab-specific). Lane 1 shows the ultrasonic supernatant
of Fab094 with HRP-conjugated anti-human IgG; lane 2 was the culture
supernatant of Fab094 with HRP-conjugated anti-human IgG.
doi:10.1371/journal.pone.0019848.g002
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against rabies comparable with that provided by 20 IU/kg HRIG.
These data illustrated that Fab094 and Fab094-CPNPs had strong
neutralizing potential, and Fab094-CPNPs had stronger neutral-
izing potential than Fab094 at an equivalent concentration. The
survival rate in mice treated with Fab094 or Fab094-CPNPs alone
was 12.5% and 25%, respectively. This result also showed that
antibody without vaccine did not prevent rabies infection.
Statistical analysis showed that the survival rates of groups with
40 IU/kg Fab094, 32 IU/kg and 40 IU/kg Fab094-CPNPs were
significantly higher than control group (P,0.05). Necropsy of the
brain showed that all mice had infection with rabies virus (data not
shown).
Discussion
Rabies virus entry occurs through wounds or direct contact with
mucosal surfaces. For PEP, early local injection-site reactions that
consist of erythema and itching are not uncommon with purified
HRIG and ERIG. Published data indicate that immunoglobulins
can be injected safely into already infected animal bite wounds
after proper wound cleaning and administration of appropriate
antibiotics [23]. Human monoclonal antibodies produced in
accordance with industrial standards could provide a good
solution to the current global shortage of HRIG [20]. To date,
some antibody engineering technologies have been developed to
achieve this goal: fully humanized antibodies are derived by
immunizing transgenic mice, and selecting the recombinant
human antibody native or immunized phage display libraries. In
comparison to other technologies, antibody phage display has the
advantages of being inexpensive and highly efficient. The study of
antigen panning, sequencing and purification to obtain a specific
antibody fragment typically can be completed within several
weeks. We have successfully constructed a human immunized Fab
phage library with a diversity of 6.7610
8, and that library was
used in the present study to generate a neutralization Fab
fragment against rabies virus.
Figure 3. IP and MS analysis of Fab094 binding to rabies virus protein. (A) Proteins immunoprecipitated by Fab094 were separated by SDS-
PAGE and probed with mAb(C86307M) by Western blot. (M): protein marker. (1): One protein was recognized by mAb(C86307M). The molecular
weight of the protein was about 67 kDa. (2): BHK-21 lysate was used as the negative control to replace Fab094 in the IP. (B): MS spectrums of
fragment ions were from the 67 kDa protein. Eight major (m/z=175.038, 262.012, 362.927, 463.973, 634.074, 737.207, 852.205, 1370.649) ions were
detected.
doi:10.1371/journal.pone.0019848.g003
Table 1. Amino-acid residue sequences of matched peptides.
Relative intensity Amino-acid residue
1 175.038 KHFRPTP DACR
2 262.012 YEES LHNPYPDYHW LR
3 362.927 LGTSCDI FTNSR
4 463.973 TCGFVD ER
5 634.074 LCGVLGLR
6 737.207 EECLDALESIM TTNPVSFRR
7 852.205 DGDE VEDFVEVHLP DVHK
8 1370.649 AESIQ HSFGETGRKV SVTSQSGRVI SSWESYK
doi:10.1371/journal.pone.0019848.t001
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virus-infected cells stained with Fab094; B: normal BHK-21 cells with Fab094.
doi:10.1371/journal.pone.0019848.g004
Figure 5. Kaplan-Meier survival curves for Kunming mouse after rabies virus challenge. Kunming mice (17 groups of eight mice, 10–12 g)
were infected with 100LD50/0.05 ml rabies virus CVS-11. Three hours later, prophylaxis was initiated with vaccine (diluted with PBS; Chiron Behring
Vaccines) alone, single antibody (Fab094 or Fab094-CPNPs) alone, vaccine plus HRIG (20 IU/kg; Taibang Ltd., China), or vaccine plus 40, 32, 20, 2 or
0.5 IU/kg single monoclonal antibody (Fab094 or Fab094-CPNPs). As a negative control, one group was treated with PBS. On day 7, mice were
vaccinated with rabies vaccine again, except for the negative control group. The mice were examined daily for clinical signs of rabies and death. The
mice were maintained and evaluated at up to 28 days after infection. The mice were monitored twice daily and were killed when clinical signs of
rabies appeared. Kaplan-Meier survival curves are shown for days 0–15. The mice were monitored until day 28 after treatment (no additional deaths
occurred between days 16 and 28).
doi:10.1371/journal.pone.0019848.g005
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antibody library using RNA from human peripheral blood
lymphocytes from 45 rabies-vaccinated volunteers. The neutral-
izing human Fab antibody fragments were selected from this
library with whole rabies virus particles. Among the selected Fab
clones, Fab094 revealed neutralizing activity against strain CVS-
11 when tested by RFFIT. Immunoprecipitation and MS assay
showed that the Fab094 fragments bound to the glycoprotein of
CTN strain, which is epidemic in China [13].
The aim of the present study was to generate a human Fab
fragment that recognized rabies virus glycoprotein and was able to
inhibit virions binding to and entering humanized cells, therefore,
the antigen panning strategy was crucial. To obtain phage clones
of high specificity and affinity for rabies virus, we maximized the
library density of phage to about 10
14 pfu/ml, which is the highest
concentration to which phage can be condensed for the first round
of panning. This procedure yielded an average of 2.5610
5 clones.
In addition, the wash step in the first round was not sufficiently
stringent to elute phage for amplification, to increase the chance
that all of the rabies-virus-binding phages were collected. If there
were ,10
5 eluted phages, the specific phage might have failed to
be enriched. The conventional panning method is to use
recombinant antigen coated on a solid substrate; usually a
microtiter plate. However, the antigen on the virus surface might
be different from the purified protein because of the conforma-
tional changes, and this could decrease the chances of isolating
phages that bind to the protein. In the present study, the whole
virus particles used as a vaccine were used to coat the
immunoplates for phage panning, to select the antibody that
bound to the antigen in native comformation.
Several studies have confirmed that the glycoprotein is the
important antigen of rabies virus; it is capable of inducing and
binding neutralizing antibodies to the virus, which confer
immunity against a lethal challenge infection with the virus
[24,25]. In the present study, western blotting (Fig. 2) and MS
(Fig. 3) showed that Fab094 could bind with the 67 kD
glycoprotein of rabies virus, which suggests that Fab094 might
have the ability to neutralize rabies virus.
Ando et al. have described two rabies-virus-neutralizing Fabs
isolated from a combinatorial human Fab phage display library,
but two antibodies exhibited neutralizing activity with an infected
cell count reduction of 76% or 57% at a dilution of 1:2, and of
20% or 41% at a dilution of 1:4 [1]. In the present study, RFFIT
was used to measure Fab094 and Fab094-CPNPs. The data
showed that the titration by RFFIT was 200.11 IU/mg (Fab094)
and 246.12 IU/mg (Fab094-CPNPs). The data also indicated that
Fab094-CPNPs had higher neutralization activity than Fab094 at
an equivalent concentration.
Furthermore, in vivo studies indicated that treatment of
Kunming mice with each rabies antibody resulted in protection
equivalent to that offered by HRIG when mice were challenged
with a lethal rabies virus dose. In the vaccine only group, the
survival rate was low (25%). This could have been because the
injection site of rabies was in the foreleg of the mice, which was
close to the central nervous system and brain, or perhaps the virus
had invaded the neurocytes before vaccine-induced antibody
production. This result also suggests that vaccine alone cannot
provide sufficient survival, and antibody must be used in category
III PEP. Similarly, antibody alone did not provide sufficient
protection. This might be related to antibody degradation in vivo.
In mice treated with Fab094 and vaccine, the survival rates
increased with dosage. A clear dose effect was observed in the mice
treated with 40, 32, 20, 8, 2 and 0.5 IU/kg Fab094, which
produced survival rates of 75%, 50%, 37.5%, 37.5%, 37.5% and
37.5%, respectively. This indicated that 40 IU/kg Fab094
provided a level of protection against rabies comparable with that
provided by 20 IU/kg HRIG, which illustrated the strong
neutralizing potency of Fab094. For Fab094-CPNPs, 8 IU/kg
antibody plus vaccine provided a protective rate that was equal to
that with 20 IU/kg HRIG plus vaccine. The reasons for this
phenomenon should be studied further. Taken together, these
results indicate that the human Fab094 and Fab094-CPNPs,
especially the latter, might be efficacious candidate drugs to
replace RIG for rabies PEP.
In conclusion, the current study describes the isolation of
human Fabs with rabies-virus-neutralizing activity from a human
immunized phage display library using peripheral blood lympho-
cytes from 45 rabies hyper-immune volunteers in China. In
addition, we developed Fab094-CPNPs and tested their efficacy by
in vitro neutralization assay. This conclusion was confirmed by an
in vivo Kunming mice challenge model. These results demonstrate
that human Fab094 and Fab094-CPNPs might be efficacious
candidate drugs to replace RIG for rabies PEP.
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